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dysplasia or villous architecture, rather than tu-
bulovillous architecture.
The inadvertent reversal of data on cancer 
detection by the stool DNA test and FIT in Table 3 
of my article notwithstanding, the thrust of the 
message of Table 3 is that stool-based tests for 
advanced adenoma do not fare well as compared 
with colonoscopy; this has been adroitly shown 
to be valid in the studies by Imperiale et al. and 
Quintero et al. (cited as references 5 and 61 in 
my article, respectively). The assumption by Itz-
kowitz and Ahlquist that stool DNA testing 
might reach a sensitivity of 90% by a second 
round of screening at 3 years is an estimated 
outcome that has not been proved. Stool DNA 
testing is an appealing approach to screening, 
but it involves several obstacles,2 including cost-
ineffectiveness, since a positive test requires 
colonoscopy as a second procedure.3,4
Castellsagué and colleagues note mutations 
that are associated with colon-cancer syndromes. 
Although a discussion of genetic syndromes was 
not a goal of my article, these mutations were 
noted in a reference to an article by Stoffel and 
Boland (cited as reference 15 in my article).
Williamson B. Strum, M.D.
Scripps Clinic Medical Group 
La Jolla, CA 
fstrum@ aol . com
Since publication of his article, the author reports no further 
potential conflict of interest.
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Point-of-Care Warfarin Monitoring in the ROCKET AF Trial
To the Editor: On February 5, 2016, the Euro-
pean Medicines Agency (EMA) released an assess-
ment report on rivaroxaban (Xarelto), in which it 
described Bayer’s comparison of the international 
normalized ratio (INR) values obtained by the 
Alere INRatio Monitor System (formally known 
as the Hemosense INRatio device) and those ob-
tained by a central laboratory on samples col-
lected at weeks 12 and 24 during the ROCKET AF 
trial.1 Although the point-of-care device reported 
lower INR values than those shown by the labo-
ratory results, the error was not influenced by 
either anemia or conditions causing elevated fi-
brinogen levels. Since this finding negates the 
fundamental assumption in the post hoc analysis 
of the ROCKET AF data by Patel et al.,2 how 
should their results be interpreted? Of the 767 
central-laboratory samples with an INR of more 
than 4 at week 12, the point-of-care device re-
ported values of less than 3 for 219 samples 
(29%).1 Although the EMA found insufficient 
evidence to alter the benefit–risk conclusion of 
the original rivaroxaban study, the agency did 
not address several important questions. How 
many warfarin-treated patients had major bleed-
ing as a result of this error in the point-of-care 
device? Did this error result in a change in the 
percentage of time that patients receiving warfa-
rin were in the therapeutic range? Answers to 
these questions could alter the relative benefit–
risk relationship between rivaroxaban and warfa-
rin. They could also diminish the validity of the 
ROCKET AF study.3
J. Robert Powell, Pharm.D.
University of North Carolina 
Chapel Hill, NC 
bob . powell49@ gmail . com
No potential conflict of interest relevant to this letter was re-
ported.
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The authors reply: In response to the com-
ments of Powell and to provide further insight, 
we now present the results of additional analyses 
using central-laboratory INR measurements on 
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stored blood samples that were drawn on the 
same day that point-of-care tests were performed 
at 12 weeks and 24 weeks (paired samples) in the 
ROCKET AF trial. Paired samples at either time 
point were obtained from 87% of the trial patients 
(Table S1 in the Supplementary Appendix, avail-
able with the full text of this letter at NEJM.org). 
These paired samples represent 22,250 of 356,654 
total point-of-care INR tests (6%) that were per-
formed. At baseline, more patients with paired 
samples were male and had a history of greater 
use of vitamin K antagonists than did those 
without paired samples (Table S2 in the Supple-
mentary Appendix).
We used the discrepancy criteria of the Inter-
national Organization for Standardization1 to de-
fine discrepancies in measurements of the pro-
thrombin time and INR between point-of-care 
tests and central-laboratory values; the Food and 
Drug Administration (FDA) requires 90% agree-
ment (i.e., ≤10% discrepancy) for equivalence. 
We found that among samples obtained from 
patients receiving warfarin, discrepant INR val-
ues between the point-of-care and central-labo-
ratory testing were present in 13% of the sam-
ples obtained at either 12 weeks or 24 weeks and 
in 4% of the samples obtained at both time 
points (Tables S3 and S4 in the Supplementary 
Appendix). These discrepancies were unrelated 
to the presence of conditions (e.g., inflamma-
tory disorders, infections, and anemia) that are 
listed in the FDA recall notice. The point-of-care 
INR was in the same range with respect to treat-
ment criteria (i.e., <2, 2 to 3, or >3) as the labo-
ratory INR in approximately 60% of the paired 
values, in a lower range in slightly more than 
one third, and in a higher range in 4% (Table S5 
in the Supplementary Appendix). The time that 
patients spent in the therapeutic range accord-
ing to discrepancy is presented in Table S6 in the 
Supplementary Appendix.
Event rates among warfarin-treated patients 
with discrepant values were higher for both bleed-
ing and stroke than among those with nondis-
crepant values (Tables S7, S8, and S9 in the Sup-
plementary Appendix). If INR values that were 
potentially underestimated by the point-of-care 
device had led to clinical events, then higher 
rates of bleeding but not of stroke would have 
been expected in the patients receiving warfarin. 
We also examined discrepancies between the 
point-of-care and central-laboratory results among 
rivaroxaban-treated patients (Tables S10 and S11 
in the Supplementary Appendix). Patients receiv-
ing rivaroxaban who had discrepant point-of-
care results also had higher bleeding rates but 
lower stroke rates (Table S12 in the Supplemen-
tary Appendix).
We performed an analysis of the trial out-
comes after the removal of all patients with 
discrepant point-of-care and central-laboratory 
values (Tables S13 through S18 in the Supple-
mentary Appendix). For the primary efficacy end 
point of stroke or systemic embolism, among 
patients with nondiscrepant values at both time 
points, there were 1.46 events per 100 patient-
years with rivaroxaban and 1.37 events per 100 
patient-years with warfarin (unadjusted hazard 
ratio, 1.06; 95% confidence interval [CI], 0.78 to 
1.45; P = 0.70 for superiority; P = 0.03 for non-
inferiority) (Table S15 in the Supplementary Ap-
pendix). For the principal safety end point of 
major and nonmajor clinically relevant bleeding, 
there were 11.36 events per 100 patient-years 
with rivaroxaban and 12.42 events per 100 pa-
tient-years with warfarin (unadjusted hazard ra-
tio, 0.92; 95% CI, 0.82 to 1.03; P = 0.13).
These results are consistent with the origi-
nally reported overall trial results. However, we 
acknowledge the limitations of these analyses. 
To be fully informative, we would need to pro-
vide paired central-laboratory and point-of-care 
INR values throughout the trial, and these values 
are not available.
Manesh R. Patel, M.D. 
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Duke Clinical Research Institute 
Durham, NC 
manesh . patel@ duke . edu
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This letter was published on July 6, 2016, at NEJM.org.
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